InvivoGen Therapeutics, From Genes to Therapeutics
InvivoGen Therapeutics is dedicated to the research, development and manufacturing of gene therapy and immunotherapy products for the treatment of serious and life-threatening diseases.
The initial focus of InvivoGen Therapeutics is the development of next generation plasmid vectors for the treatment of cancers and genetic diseases. Our innovative non-viral gene therapy approach offers substantial improvements over existing therapies in terms of safety and efficacy. A phase I/II clinical trial is expected to start early 2008.
The initial focus of InvivoGen Therapeutics is the development of next generation plasmid vectors for the treatment of cancers and genetic diseases. Our innovative non-viral gene therapy approach offers substantial improvements over existing therapies in terms of safety and efficacy. A phase I/II clinical trial is expected to start early 2008.
Collaborations
Our key partners are:Cancer-Bio-Health Cluster
INSERM
CNRS
...
News
04/20/2007
Certification of the TherGAP project by the Cancer-Bio-Health Cluster...
12/26/2006
Funding of the "IgA Therapy" project by the Cancer-Bio-Health Cluster...
GMP facility
InvivoGen Therapeutics operates its own GMP facility for the production of clinical lots of plasmid DNA for gene therapy trials...
Technologies
CpG-free plasmidic vectors for the treatment of genetic diseases and cancers
Recombinant monoclonal IgA antibodies for the treatment of cancers and inflammation